Verona Pharma plc
VRNA
Price:
$38.81
Market Cap:
$3.18B
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in...[Read more]
Industry
Biotechnology
IPO Date
2017-04-28
Stock Exchange
NASDAQ
Ticker
VRNA
PE Ratio
[-19.40]
ROE
[-79.64%]
Current Ratio
[13.03]
Dividend Yield
[0%]
Enterprise Value
[2.96B]
Dividend History
The ROE as of November 2024 (TTM) for Verona Pharma plc (VRNA) is -79.64%
According to Verona Pharma plc’s latest financial reports and current stock price. The company's current ROE is -79.64%. This represents a change of 245.35% compared to the average of -23.06% of the last 4 quarters.
Verona Pharma plc (VRNA) Historical ROE (quarterly & annually)
How has VRNA ROE performed in the past?
The mean historical ROE of Verona Pharma plc over the last ten years is -44.52%. The current -79.64% ROE has changed 78.88% with respect to the historical average. Over the past ten years (40 quarters), VRNA's ROE was at its highest in in the September 2021 quarter at 6.57%. The ROE was at its lowest in in the June 2024 quarter at -42.14%.
Average
-44.52%
Median
-30.72%
Minimum
-132.76%
Maximum
-14.56%
Verona Pharma plc (VRNA) ROE by Quarter and Year
Discovering the peaks and valleys of Verona Pharma plc ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 506.57%
Maximum Annual ROE = -14.56%
Minimum Annual Increase = -89.03%
Minimum Annual ROE = -132.76%
| Year | ROE | Change |
|---|---|---|
| 2023 | -21.81% | -26.84% |
| 2022 | -29.81% | -20.60% |
| 2021 | -37.55% | 6.54% |
| 2020 | -35.24% | -62.64% |
| 2019 | -94.32% | 198.27% |
| 2018 | -31.62% | 23.24% |
| 2017 | -25.66% | 76.24% |
| 2016 | -14.56% | -89.03% |
| 2015 | -132.76% | 506.57% |
| 2014 | -21.89% | -82.07% |
Verona Pharma plc (VRNA) Average ROE
How has VRNA ROE performed in the past?
The current ROE of Verona Pharma plc (VRNA) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-29.72%
5-year avg
-43.75%
10-year avg
-44.52%
Verona Pharma plc (VRNA) ROE vs. Peers
How is VRNA’s ROE compared to its peers?
Verona Pharma plc’s ROE is greater than Ventyx Biosciences, Inc. (-54.94%), greater than IDEAYA Biosciences, Inc. (-19.42%), less than Protagonist Therapeutics, Inc. (34.68%), greater than Syndax Pharmaceuticals, Inc. (-64.34%), greater than Day One Biopharmaceuticals, Inc. (-22.40%), greater than X4 Pharmaceuticals, Inc. (-32.51%), greater than Inozyme Pharma, Inc. (-88.42%), greater than Acumen Pharmaceuticals, Inc. (-32.99%), greater than Mereo BioPharma Group plc (-69.11%), greater than Terns Pharmaceuticals, Inc. (-32.76%), greater than Amylyx Pharmaceuticals, Inc. (-85.39%), greater than MoonLake Immunotherapeutics (-15.89%), greater than Mirati Therapeutics, Inc. (-40.45%), greater than Apellis Pharmaceuticals, Inc. (-103.92%), greater than Akero Therapeutics, Inc. (-32.52%), greater than Madrigal Pharmaceuticals, Inc. (-71.78%), greater than Viking Therapeutics, Inc. (-12.73%),
| Company | ROE | Market cap |
|---|---|---|
| -54.94% | $130.81M | |
| -19.42% | $2.32B | |
| 34.68% | $2.77B | |
| -64.34% | $1.37B | |
| -22.40% | $1.38B | |
| -32.51% | $57.64M | |
| -88.42% | $180.51M | |
| -32.99% | $142.39M | |
| -69.11% | $575.61M | |
| -32.76% | $491.80M | |
| -85.39% | $361.25M | |
| -15.89% | $3.43B | |
| -40.45% | $4.12B | |
| -103.92% | $3.83B | |
| -32.52% | $2.28B | |
| -71.78% | $7.58B | |
| -12.73% | $5.86B |
Build a custom stock screener for Verona Pharma plc (VRNA) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Verona Pharma plc using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Verona Pharma plc (VRNA) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Verona Pharma plc or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Verona Pharma plc's ROE?
How is the ROE calculated for Verona Pharma plc (VRNA)?
What is the highest ROE for Verona Pharma plc (VRNA)?
What is the 3-year average ROE for Verona Pharma plc (VRNA)?
What is the 5-year average ROE for Verona Pharma plc (VRNA)?
How does the current ROE for Verona Pharma plc (VRNA) compare to its historical average?